Viewing nowMegavartan Tablets 80 mg (Valsartan)
Valsartan 80mg
Tablet · Prescription medication
L&C Bio Co., Ltd.

MFDS item code 202001651 · Approved 2020.03.10 · Insurance code 060500860
Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction
This medication effectively lowers blood pressure in individuals with essential hypertension, helping to maintain vascular health. It is also used in heart failure patients (particularly those in NYHA Class II-IV) who have difficulty taking ACE inhibitors, contributing to improvement in cardiac function. For patients with left ventricular dysfunction or reduced contractility after myocardial infarction, it helps to reduce mortality risk. It is used effectively to enhance the health of patients with various cardiovascular issues.
1. Essential hypertension Take with water during or between meals. If possible, it is recommended to take the medicine at the same time each day (e.g., in the morning). 1) Adults: The recommended dose, regardless of sex or race, is 80 mg of valsartan orally once daily. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum effect after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg/day or a diuretic may be coadministered. If further blood pressure reduction is required, the dose may be increased to a maximum of 320 mg/day. 2) Older adults (75 years and older): Start treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medicine once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, start treatment with 40 mg of this medicine once daily; do not exceed 80 mg/day. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily, and it may be increased to 80 mg or 160 mg per dose. When a diuretic is coadministered, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy of this medicine with an ACE inhibitor and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily, followed over several weeks by dose increases, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Dose reduction should be considered if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment : No dose adjustment is necessary when creatinine clearance is 10 mL/min or higher; however, do not administer this medicine to patients with creatinine clearance less than 10 mL/min or to patients on dialysis, because there is no experience with its use in these patients. 5. Patients with hepatic impairment : The daily dose of this medicine should preferably not exceed 80 mg in patients with mild to moderate hepatic impairment. If doses of 80 mg/day or more are administered, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age. The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age.
This medication can cause serious harm to the fetus if taken during the second and third trimesters of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. Women who are pregnant or may become pregnant, as well as breastfeeding women, should not use this medication. Patients with severely impaired liver function, cirrhosis, or biliary obstruction should also avoid this medication. Patients with hypersensitivity or a history of hereditary angioedema should also avoid taking it. It is not administered to patients with severely impaired renal function, primary hyperaldosteronism, or certain kidney diseases. Caution is needed in elderly patients, those with hyperkalemia, or mild liver impairment, and dosage adjustments may be necessary. Patients with valvular heart disease or cardiovascular disease, as well as those in a state of fluid depletion, should be cautious as this medication may cause a rapid drop in blood pressure. As it lowers blood pressure, dizziness or fainting may occur when first taking the medication; if these symptoms occur, medical personnel should be informed immediately. Headache, dizziness, cough, diarrhea, fatigue, and other side effects may occur during treatment, but most are mild. Patients with heart failure or those post-myocardial infarction should regularly monitor renal function and electrolytes, and consult medical personnel if symptoms worsen. This medication may interact when taken with other antihypertensive agents or diuretics, so all medications being taken should be reported to medical personnel. Specifically, caution is warranted when taken with potassium-sparing diuretics or potassium supplements as blood potassium levels may rise dangerously high. It is safest not to use this medication during pregnancy or breastfeeding; it is recommended to discontinue breastfeeding if using this medication. Safety and efficacy have not been established for children and adolescents under 18 years of age, so it is advisable not to use it. In case of overdose, extraordinarily low blood pressure or altered consciousness may occur, requiring immediate emergency treatment. This medication should be kept out of the reach of children and transferring to other containers should be avoided.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture, so it must be stored in a tightly sealed container. Additionally, it is important to keep it in a cool place, below 30 degrees Celsius, to maintain its effectiveness.
Pink round film-coated tablets
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowValsartan 80mg
Tablet · Prescription medication
L&C Bio Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.